Pharmacy

Advancement in TED treatment is a bright spot

June 30, 2021

FDA approval of teprotumumab as therapeutic offers hope for patients.

Comparable conscious sedation methods address individual patient needs

April 14, 2021

Sublingual troche sedation represents attractive anesthesia option for specific subset of patients with cataracts.

Investigators uncover health care disparities among US patients

April 02, 2021

Study highlights role of demographic and socioeconomic characteristics in treatment.

Investigators zoom in on future of dry eye treatment

March 02, 2021

Autologous serum eye drops and blood products offer hope to patients.

Visus CEO updates on lead product candidate, 2021 pipeline

January 27, 2021

Visus Therapeutics CEO Ben Bergo shares an update on the status of its lead product candidate for presbyopia treatment as well as what's in the company's pipeline for 2021.

Analyzing opioid prescription patterns of US retina specialists

November 16, 2020

Investigators looked at trends by geographic variation in practice patterns, perceptions toward opioids, and patient population

(AAO) Genentech provides update on presentations, product portfolio

November 13, 2020

Chris Brittain, MBBS, BSc, MBA, MRCOphth, vice president and global head of ophthalmology product development for Genentech, provides an overview of the company’s podium presentations from the PDS with ranibizumab to faricimab.

What keeps you up at night in ophthalmology: Part II

October 18, 2020

Pharmaceutical representatives share what keeps them up at night within the ophthalmic space.

Bausch Health: Spin-off of eye health business

August 06, 2020

This action will result in 2 separate companies,

Glaucoma 360: Drug delivery contact lens technology

July 17, 2020

ICYMI: Chris Adams, CEO of Diopter Corp, discusses the company's drug delivery contact lens technology in the pipeline that works to treat ocular surface disease, during the 2020 Glaucoma 360 meeting in San Francisco, California.